Currently, therapeutic choices for patients with pulmonary hypertension (PH) are limited. This paper reveals that dipeptidyl peptidase IV inhibition alleviates pulmonary arterial remodeling in PH by decreasing the proliferation and migration of pulmonary arterial smooth muscle cells by regulating PTEN/AKT/MAPK signaling. Therefore, soluble DPP-4 might be a diagnostic or prognostic marker for PH; and DPP-4 inhibitors, potential treatments.
- Jian Xu
- Jingjing Wang
- Hui Kong